In light of controversy over the recent semaglutide drug shortages for the diabetes patients they're indicated for, one doctor illuminates another side of the case. From the Kardashians to that person ...

GLP-1 weight loss drugs — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — work by suppressing appetite and delaying the rate at which your stomach empties.

Credit: Getty Images Until semaglutide, weight loss of 15% to avoid obesity-related complications was only achieved through bariatric surgery. In clinical trials, semaglutide proved to be superior to ...

He explained that Mounjaro is now becoming the preferred choice over semaglutide, which is better known as Ozempic or Wegovy, with sales set to reach reach $34 billion a year by 2029. Dr Porter ac ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

For a time, pharmacies were able to make compounded versions of drugs that had semaglutide or tirzepatide as the active ingredient because of a shortage. In December 2024, the FDA announced that ...

Then, in February, the FDA determined that the shortage of semaglutide, the active ingredient in Ozempic and Wegovy, had also been resolved. It meant compounding pharmacies had to stop making ...

New animal research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment ...

Semaglutide significantly improved liver health in patients with MASH, reducing liver inflammation in nearly two-thirds of those treated and improving fibrosis in over a third, according to a global ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing cardiovascular disease but not diabetes, ...

Weight loss injections may have an anti-cancer effect "beyond weight loss", a new study suggests. Obesity is linked to 13 different cancers. Scientists have long known that losing weight can slash ...

The phase 3b open-label, randomized controlled trial showed that patients treated with tirzepatide vs semaglutide lost an average of 20.2% vs 13.7% of their baseline weight over the 72 weeks.